Holen Sie sich die Stockscreener-App
12.52
0.39%
-0.075
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
Phathom Pharmaceuticals CEO drives new momentum after DDW2026 to advance GI patient care - Traders Union
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline - Yahoo Finance
Phathom outlines $320M-$345M 2026 revenue as it targets operating profitability by Q3 - MSN
How Phathom Pharmaceuticals Inc. (PHAT) Affects Rotational Strategy Timing - Stock Traders Daily
147,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Hussman Strategic Advisors Inc. - MarketBeat
How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks - Yahoo Finance
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX) - The Globe and Mail
Phathom Pharmaceuticals Signals Strong Growth on Earnings Call - The Globe and Mail
Earnings call transcript: Phathom Pharmaceuticals beats Q1 2026 EPS expectations - Investing.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5%Should You Buy? - MarketBeat
A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $25 to $28 - Moomoo
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2026 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals announces DDW2026 booth and team participation in Chicago - Traders Union
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting - The Manila Times
GERD drug VOQUEZNA gets 3 posters and a May 4 presentation at DDW - Stock Titan
Phathom Pharmaceuticals Inc (PHAT) Q1 2026 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Phathom Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PHAT) 2026-04-30 - Seeking Alpha
Phathom Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Phathom Pharmaceuticals, Inc. (PHAT) reports Q1 loss, tops revenue estimates - MSN
Phathom (PHAT) Q1 2026 Earnings Transcript - The Globe and Mail
Phathom Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Phathom Pharmaceuticals Reports Q1 2026 Results: VOQUEZNA Prescriptions Surge, Revenue Doubles, Operating Profitability Expected in Q3 - Minichart
Phathom Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 16.2% After Earnings Miss - MarketBeat
Earnings call transcript: Phathom Pharmaceuticals beats EPS expectations in Q1 2026 By Investing.com - Investing.com South Africa
Is Phathom Pharmaceuticals (PHAT) Fairly Valued After Q1 2026 Ea - GuruFocus
Earnings call transcript: Phathom Pharmaceuticals beats EPS expectations in Q1 2026 - Investing.com
Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Q1 2026 Phathom Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Reports Q1 Product Revenue $58.3M, vs. FactSet Est of $55.9M - marketscreener.com
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q1 Adjusted Loss $0.18 per Share, vs. FactSet Est of $-0.21 - marketscreener.com
Phathom Pharmaceuticals Q1 2026 earnings preview - MSN
8-K: Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Updatemoomoo - Moomoo
Phathom Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
Phathom Pharmaceuticals reports Q1 2026 revenue $58.3M, narrows net loss to $30.4M - TradingView
1.35M VOQUEZNA prescriptions filled; Phathom expects Q3 operating profitability - Stock Titan
VOQUEZNA growth moves Phathom (NASDAQ: PHAT) closer to profitability - Stock Titan
Phathom Pharmaceuticals (NASDAQ: PHAT) doubles Q1 2026 revenue, cuts loss - Stock Titan
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update - ChartMill
Phathom upgraded at Barclays following pullback, Voquezna optimism - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Pfizer (PFE) and Guardant Health (GH) - The Globe and Mail
Phathom Pharmaceuticals Inc (PHAT) Q1 2026: Everything You Need To Know Ahead Of Earnings - GuruFocus
Phathom Pharmaceuticals to present VOQUEZNA clinical data at DDW2026 event - Traders Union
Phathom says FDA confirmed Voqueza exclusivity through May 2032 - MSN
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating - Moomoo
Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet - MSN
Phantom slumps 12%; prices $130M stock at $16 per share - MSN
Barclays upgrades Phathom Pharmaceuticals (PHAT) - MSN
HC Wainwright & Co. Maintains Phathom Pharmaceuticals (PHAT) Buy Recommendation - MSN
Phathom Pharmaceuticals brings senior marketing leader to ThinkDHC patient engagement event - Traders Union
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):